COVID-19 vaccines by contract size manufacturer and country 2021

As of March 9, 2021, India has secured some 2.2 billion COVID-19 vaccine doses through contracts in total. India chose to purchase vaccines manufactured by AstraZeneca (Oxford), Novavax, and the Russian Gamaleya Institute. However, the overwhelming majority of these doses have yet to be produced and delivered. This statistic shows the size of COVID-19 vaccine contracts based on number of doses secured by countries through contracts with manufacturers. The AstraZeneca/Oxford vaccine is by far the most sought COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines need ultra cold storage.

Size of COVID-19 vaccine contracts between countries and manufacturers as of March 2021 (in million doses)

Characteristic	AstraZeneca/Oxford	Novavax	Biontech/Pfizer	Gamaleya	Moderna	Johnson & Johnson
India	1,000	1,000	-	200	-	-
European Union	300	-	500	-	310	200
United States	300	110	300	-	300	100
Covax	300	-	-	-	-	-
United Kingdom	100	60	40	-	17	30
Japan	120	-	144	-	50	-
Indonesia	50	50	-	-	-	-
Brazil	100	-	-	100	-	-
China	200	-	-	-	-	-
Canada	20	52	40	-	44	10
Mexico	77	-	34	64	-	-
Australia	54	51	20	-	-	-
Russia	-	-	-	160	-	-
Latin America bloc	150	-	-	-	-	-
South Korea	20	40	26	-	40	4

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

March 2021

More information

Region

Worldwide

Survey time period

as of March 9, 2021

Supplementary notes

This is a selection of the most prominent vaccines (already approved or on track to be approved) and some countries/regions.
When country contracts include a range of doses to be purchased, we count the lower number. On Dec. 23, Canada’s contracts were updated to reflect those details verified by the government.The Latin America bloc covers all countries in the region except Brazil. The European Union bloc represents the 27 countries of the European Union. The Covax agreement extends to most countries in the world, including many in Africa that wouldn’t otherwise be covered. Jurisdictions without a population figure, such as Somalia and Syria, have been omitted. The Middle East bloc covers U.A.E., Egypt, Bahrain and Jordan. Partnerships involving local manufacturers are listed under the original vaccine developer.

Citation formats